OHSU
Return to Listing

2 result(s) for LGX818

PI Name Protocol # Title
Matthew Taylor IRB00010427 [Quroum] Modular Phase II Study to Link Targeted Therapy to Patients with Pathway Activated Tumors: Module 4 - LGX818 for Patients with BRAFV600E Mutated Tumors
Matthew Taylor IRB00010630 CLGX818X2109: The LOGIC 2 trial, A phase II, multi-center, open-label study of sequential LGX818/MEK162 combination followed by a rational combination with targeted agents after progression, to overcome resistance in adult patients with locally advanced or metastatic BRAF V600 melanoma.
 
For more information:
Email: trials@ohsu.edu
Call: 503-494-1080
 

You may qualify for additional trials within our Phase 1 Program